Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: Focus on davunetide (NAP)

Neuropeptides

Volumn 47, Issue 6, 2013, Pages 489-495

  Magen, Iddo ^a   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activity dependent neuroprotective protein (ADNP); Axonal transport; Davunetide; NAP; Neurodegenerative diseases; Neurological disorders

Indexed keywords

DAVUNETIDE; EPOTHILONE D; IXABEPILONE; LAULIMALIDE; N ACETYLASPARTIC ACID; NOCODAZOLE; PACLITAXEL; PELORUSIDE; PLACEBO; UNCLASSIFIED DRUG; ZINC;

AGING; ALCOHOL INTOXICATION; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; BRAIN FUNCTION; CELL DEATH; CELL PROLIFERATION; COGNITION; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; GENE OVEREXPRESSION; HEADACHE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; LEARNING; LONGEVITY; MEMORY; MICROTUBULE; MICROTUBULE ASSEMBLY; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL MEMBRANE; MITOSIS SPINDLE; MOTOR PERFORMANCE; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE FIBER TRANSPORT; NERVOUS SYSTEM DEVELOPMENT; NEURAL TUBE DEFECT; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; TAUOPATHY; VENTRAL TEGMENTUM; WORKING MEMORY;

ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN; ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN (ADNP); AD; ADNP; ALS; ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AXONAL TRANSPORT; DAVUNETIDE; KNOCKOUT; KO; MANGANESE ENHANCED MAGNETIC RESONANCE IMAGING; MAP; MEMRI; MICROTUBULE ASSOCIATED PROTEIN; NAP; NEURODEGENERATIVE DISEASES; NEUROLOGICAL DISORDERS; STABLE TUBULE ONLY PEPTIDE; STOP;

ANIMALS; ANTINEOPLASTIC AGENTS; AXONAL TRANSPORT; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MICE; MICROTUBULES; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS; TAU PROTEINS; TAUOPATHIES; TUBULIN MODULATORS;

EID: 84887972203     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2013.10.011     Document Type: Review

References (108)

1. Andrieux A., et al. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol. Psychiatry 2006, 60(11):1224-1230.
2. Baselga J., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 2009, 27(4):526-534.
3. Bassan M., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 1999, 72(3):1283-1293.
4. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52(1):39-59.
5. Boom A., et al. Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells. Biochim. Biophys. Acta 2009, 1793(6):1058-1067.
6. Bunnell C., et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin. Breast Cancer 2008, 8(3):234-241.
7. Cartelli D., et al. Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone d is neuroprotective. Sci. Rep. 2013, 3:1837.
8. Chen S., Charness M.E. Ethanol disrupts axon outgrowth stimulated by netrin-1, GDNF, and L1 by blocking their convergent activation of Src family kinase signaling. J. Neurochem. 2012, 123(4):602-612.
9. Chen S.Y., et al. Peptide-mediated protection from ethanol-induced neural tube defects. Dev. Neurosci. 2005, 27(1):13-19.
10. Chu Y., et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135(Pt. 7):2058-2073.
11. Clavaguera F., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11(7):909-913.
12. Clavaguera F., et al. "Prion-like" templated misfolding in tauopathies. Brain Pathol. 2013, 23(3):342-349.
13. Corley D.G., Moore H.R., Scheur P.J., Paul V.J. Laulimalide. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J. Org. Chem. 1988, 53:3644-3646.
14. Cowan C.M., et al. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 2010, 120(5):593-604.
15. Crume K.P., et al. Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A. J. Leukoc. Biol. 2009, 86(4):949-958.
16. Das V., Miller J.H. Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation. Eur. J. Neurosci. 2012, 35(11):1705-1717.
17. Das V., Miller J.H. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells. Brain Res. 2012, 1489:121-132.
18. de Jonge M., Verweij J. The epothilone dilemma. J. Clin. Oncol. 2005, 23(36):9048-9050.
19. Divinski I., Mittelman L., Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem. 2004, 279(27):28531-28538.
20. Divinski I., et al. Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem. 2006, 98(3):973-984.
21. Dresner E., Agam G., Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur. Neuropsychopharmacol. 2011, 21(5):355-361.
22. Erck C., et al. A vital role of tubulin-tyrosine-ligase for neuronal organization. Proc. Natl. Acad. Sci. USA 2005, 102(22):7853-7858.
23. Fellner S., et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 2002, 110(9):1309-1318.
24. Folwell J., et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a drosophila model of Alzheimer's disease. Exp. Neurol. 2010, 223(2):401-409.
25. Fournet V., et al. Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice. J. Neurochem. 2012, 123(6):982-996.
26. Furman S., et al. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 2004, 1(3):193-199.
27. Gaitanos T.N., et al. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res. 2004, 64(15):5063-5067.
28. Ganguly A., Yang H., Cabral F. Class III beta-tubulin counteracts the ability of paclitaxel to inhibit cell migration. Oncotarget 2011, 2(5):368-377.
29. Gennet N., et al. Expression of activity-dependent neuroprotective protein in the brain of adult rats. Histol. Histopathol. 2008, 23(3):309-317.
30. Golbe L.I., Ohman-Strickland P.A. A clinical rating scale for progressive supranuclear palsy. Brain 2007, 130(Pt. 6):1552-1565.
31. Gold M., et al. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr. Dis. Treat. 2012, 8:85-93.
32. Goodin S., Kane M.P., Rubin E.H. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. 2004, 22(10):2015-2025.
33. Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr. Pharm. Des. 2011, 17(31):3413-3417.
34. Gozes I., Divinski I. The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J. Alzheimers Dis. 2004, 6(Suppl. 6):S37-S41.
35. Gozes I., Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr. Alzheimer Res. 2007, 4(5):507-509.
36. Gozes I., et al. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 2000, 293(3):1091-1098.
37. Gozes I., et al. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci. 2003, 20(3):315-322.
38. Gozes I., et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005, 11(4):353-368.
39. Gozes I., et al. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr. Alzheimer Res. 2009, 6(5):455-460.
40. Gozes I., et al. NAP alpha-aminoisobutyric acid (IsoNAP). J. Mol. Neurosci. 2013, In Press.
41. Hood K.A., et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res. 2002, 62(12):3356-3360.
42. Huang H., et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 2010, 16(5):1634-1641.
43. Huzil J.T., et al. A unique mode of microtubule stabilization induced by peloruside A. J. Mol. Biol. 2008, 378(5):1016-1030.
44. Idan-Feldman A., et al. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol. Dis. 2011, 44(3):327-339.
45. Idan-Feldman A., Ostritsky R., Gozes I. Tau and caspase 3 as targets for neuroprotection. Int. J. Alzheimers Dis. 2012, 2012:493670.
46. Ikenaka K., et al. Disruption of axonal transport in motor neuron diseases. Int. J. Mol. Sci. 2012, 13(1):1225-1238.
47. Jarskog L.F., et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 2013, 38(7):1245-1252.
48. Javitt D.C., et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 2012, 136(1-3):25-31.
49. Jefford C.W., Bernardinelli G., Tanaka J., Higa T. Structures and absolute configurations of the marine toxins, latrunculin A and laulimalide. Tetrahedron Lett. 1996, 37:159-162.
50. Jouroukhin Y., Ostritsky R., Gozes I. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J. Mol. Neurosci. 2012, 48(3):597-602.
51. Jouroukhin Y., et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol. Dis. 2013, 56C:79-94.
52. Kar S., et al. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003, 22(1):70-77.
53. Leker R.R., et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002, 33(4):1085-1092.
54. Liu L., et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012, 7(2):e31302.
55. Magen I., Gozes I. Davunetide: peptide therapeutics neurologic disorders. Curr. Med. Chem. 2013, In press.
56. Mandel S., Rechavi G., Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev. Biol. 2007, 303(2):814-824.
57. Mandel S., Spivak-Pohis I., Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J. Mol. Neurosci. 2008, 35(2):127-141.
58. Matsuoka Y., et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci. 2007, 31(2):165-170.
59. Matsuoka Y., et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 2008, 325(1):146-153.
60. Merenlender-Wagner A., et al. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 2010, 31(7):1368-1373.
61. Meyer, C., Ferguson, D., Krauth, M., Wick, M. & Northcote, P., RTA 301 (peloruside): a novel microtubule stabiliser with potent in vivo activity against lung cancer and resistant breast cancer. Eur. J. Cancer Suppl, 2006. 4: p. 192-193. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Prague, Czech Republic, (for pdf, see: http://www.sciencedirect.com/science/article/B75GT-4MMF4DM-ST/2/901656de391d50b1ced2b7ad843d922a) [doi:10.1016/S1359-6349(06)70644-9].
62. Michaelis M.L., Dobrowsky R.T., Li G. Tau neurofibrillary pathology and microtubule stability. J. Mol. Neurosci. 2002, 19(3):289-293.
63. Michaelis M.L., et al. Amyloid peptide toxicity and microtubule-stabilizing drugs. J. Mol. Neurosci. 2002, 19(1-2):101-105.
64. Molnar I., et al. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90. Chem. Biol. 2000, 7(2):97-109.
65. Mooberry S.L., et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res. 1999, 59(3):653-660.
66. Morimoto B.H., et al. Pharmacokinetics of the neuroprotective peptide, NAPVSIPQ in serial samples of plasma and CSF after intravenous or intranasal administration. Drug Metab. Rev. 2006, 38(Suppl. 2):213-214.
67. Morimoto, B.H., et al., Davunetide: Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. chimica Oggi/CHEMISTRY today, 2009. 27(2): p. 16-20.
68. Mutka S.C., et al. Heterologous production of epothilone C and D in Escherichia coli. Biochemistry 2006, 45(4):1321-1330.
69. Neumann M., et al. A new family with frontotemporal dementia with intronic 10+3 splice site mutation in the tau gene: neuropathology and molecular effects. Neuropathol. Appl. Neurobiol. 2005, 31(4):362-373.
70. Ogawa F., et al. DISC1 complexes with TRAK1 and Miro1 to modulate anterograde axonal mitochondrial trafficking. Hum. Mol. Genet 2013.
71. O'Roak B.J., et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012, 485(7397):246-250.
72. O'Roak B.J., et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012, 338(6114):1619-1622.
73. Oz S., Ivashko-Pachima Y., Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One 2012, 7(12):e51458.
74. Pascual M., Guerri C. The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J. Neurochem. 2007, 103(2):557-568.
75. Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 2006, 7(9):710-723.
76. Perez E.A., et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 2007, 25(23):3407-3414.
77. Pinhasov A., et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 2003, 144(1):83-90.
78. Poggi S.H., et al. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am. J. Obstet. Gynecol. 2003, 189(3):790-793.
79. Quiñoá E., Crews P. Fijianolides, polyketide heterocyclics from a marine sponge. J. Org. Chem. 1988, 53:3642-3644.
80. Quraishe S., Cowan C.M., Mudher A. NAP (davunetide) rescues neuronal dysfunction in a drosophila model of tauopathy. Mol. Psychiatry 2013, 18(7):834-842.
81. Quraishe S., Cowan C.M., Mudher A. NAP (davunetide) rescues neuronal dysfunction in a drosophila model of tauopathy. Mol. Psychiatry 2013.
82. Rowinsky E.K., et al. Neurotoxicity of taxol. J. Natl. Cancer Inst. Monogr. 1993, 15:107-115.
83. Rowinsky E.K., et al. Clinical toxicities encountered with paclitaxel (taxol). Semin. Oncol. 1993, 20(4 Suppl. 3):1-15.
84. Sabry J., O'Connor T.P., Kirschner M.W. Axonal transport of tubulin in Ti1 pioneer neurons in situ. Neuron 1995, 14(6):1247-1256.
85. Saman S., et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer's disease. J. Biol. Chem. 2012, 287(6):3842-3849.
86. Schiff P.B., Horwitz S.B. Taxol stabilises microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 1980, 77(3):1561-1565.
87. Shiryaev N., Jouroukhin Y., Gozes I. 3R tau expression modifies behavior in transgenic mice. J. Neurosci. Res. 2010, 88(12):2727-2735.
88. Shiryaev N., et al. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr. Pharm. Des. 2011, 17(25):2603-2612.
89. Smith-Swintosky V.L., et al. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J. Mol. Neurosci. 2005, 25(3):225-238.
90. Sparano J.A., et al. Randomised phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2010, 28(20):3256-3263.
91. Sudo H., Baas P.W. Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum. Mol. Genet. 2011, 20(4):763-778.
92. Tang L., et al. Cloning and heterologous expression of the epothilone gene cluster. Science 2000, 287(5453):640-642.
93. Taya S., et al. DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. J. Neurosci. 2007, 27(1):15-26.
94. Thomas E.S., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2007, 25(33):5210-5217.
95. Vansteenkiste J., et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J. Clin. Oncol. 2007, 25(23):3448-3455.
96. Visochek L., et al. PolyADP-ribosylation is involved in neurotrophic activity. J. Neurosci. 2005, 25(32):7420-7428.
97. Vulih-Shultzman I., et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 2007, 323(2):438-449.
98. Wani M.C., et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93(9):2325-2327.
99. West L.M., Northcote P.T., Battershill C.N. Peloruside A: a potent cytotoxic macrolide isolated from the new zealand marine sponge Mycale sp. J. Org. Chem. 2000, 65(2):445-449.
100. Wills J., et al. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol. 2010, 225(1):210-218.
101. Wilson L., Panda D., Jordan M.A. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct. 1999, 24(5):329-335.
102. Yang M.H., et al. Activity-dependent neuroprotector homeobox protein: a candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J. Proteomics 2012, 75(12):3617-3629.
103. Ye X., Tai W., Zhang D. The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol. Aging 2012, 33(6):1122e1-1122e10.
104. Yenjerla M., et al. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J. Alzheimers Dis. 2010, 19(4):1377-1386.
105. Zemlyak I., et al. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J. Neurochem. 2009, 111(5):1252-1263.
106. Zhang B., et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 2004, 24(19):4657-4667.
107. Zhang B., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA 2005, 102(1):227-231.
108. Zhang B., et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 2012, 32(11):3601-3611.